Significant Quantitative Differences in Orexin Neuronal Activation After Pain Assessments in an Animal Model of Sickle Cell Disease

被引:2
|
作者
Richardson, Kimberlei [1 ]
Sweatt, Nia [1 ]
Tran, Huy [2 ]
Apprey, Victor [3 ]
Uthayathas, Subramaniam [1 ]
Taylor, Robert [1 ]
Gupta, Kalpna [2 ,4 ]
机构
[1] Howard Univ, Coll Med, Dept Pharmacol, Washington, DC 20059 USA
[2] Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Med Sch, Box 736 UMHC, Minneapolis, MN 55455 USA
[3] Howard Univ, Coll Med, Dept Family Med, Washington, DC USA
[4] Univ Calif Irvine, Sch Med, Dept Med, Div Hematol Oncol, Irvine, CA 92717 USA
基金
美国国家科学基金会; 美国国家卫生研究院;
关键词
orexin; hyperalgesia; sickle cell; pain; hypocretin; RECEPTOR MESSENGER-RNA; NEUROPATHIC PAIN; HYPOCRETIN OREXIN; OREXIN/HYPOCRETIN; REINSTATEMENT; MODULATION; STRESS; REWARD; HYPERALGESIA; HEMOGLOBIN;
D O I
10.3389/fmolb.2020.00005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sickle cell disease is a hemoglobinopathy that causes sickling of red blood cells, resulting in vessel blockage, stroke, anemia, inflammation, and extreme pain. The development and treatment of pain, in particular, neuropathic pain in sickle cell disease patients is poorly understood and impedes our progress toward the development of novel therapies to treat pain associated with sickle cell disease. The orexin/hypocretin system offers a novel approach to treat chronic pain and hyperalgesia. These neuropeptides are synthesized in three regions: perifornical area (PFA), lateral hypothalamus (LH), and dorsomedial hypothalamus (DMH). Data suggest that orexin-A neuropeptide has an analgesic effect on inflammatory pain and may affect mechanisms underlying the maintenance of neuropathic pain. The purpose of this study was to determine whether there are neuronal activation differences in the orexin system as a result of neuropathic pain testing in a mouse model of sickle cell disease. Female transgenic sickle mice that express exclusively (99%) human sickle hemoglobin (HbSS-BERK) and age-/gender-matched controls (HbAA-BERK mice;n= 10/group, 20-30 g) expressing normal human hemoglobin A were habituated to each test protocol and environment before collecting baseline measurements and testing. Four measures were used to assess pain-related behaviors: thermal/heat hyperalgesia, cold hyperalgesia, mechanical hyperalgesia, and deep-tissue hyperalgesia. Hypothalamic brain sections from HbAA-BERK and HbSS-BERK mice were processed to visualize orexin and c-Fos immunoreactivity and quantified. The percentage of double labeled neurons in the PFA was significantly higher than the percentage of double labeled neurons in the LH orexin field of HbAA-BERK mice (*p< 0.05). The percentages of double labeled neurons in PFA and DMH orexin fields are significantly higher than those neurons in the LH of HbSS-BERK mice (*p< 0.05). These data suggest that DMH orexin neurons were preferentially recruited during neuropathic pain testing and a more diverse distribution of orexin neurons may be required to produce analgesia in response to pain in the HbSS-BERK mice. Identifying specific orexin neuronal populations that are integral in neuropathic pain processing will allow us to elucidate mechanisms that provide a more selective, targeted approach in treating of neuropathic pain in sickle cell disease.
引用
收藏
页数:12
相关论文
共 24 条
  • [1] Time-Dependent Differences on Pain Assessments After Orexin Receptor-1 Antagonism in a Mouse Model of Sickle Cell Disease
    Richardson, Kimberlei
    Ryan, Alexa
    Sweatt, Nia
    Apprey, Victor
    Taylor, Robert
    Gupta, Kalpna
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 (SUPPL 1) : 322 - 322
  • [2] Time-Dependent Differences on Pain Assessments After Orexin Receptor-1 Antagonism in a Mouse Model of Sickle Cell Disease
    Richardson, Kimberlei
    Ryan, Alexa
    Sweatt, Nia
    Apprey, Victor
    Taylor, Robert
    Gupta, Kalpna
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 : 322 - 322
  • [3] Mast Cell Activation Syndrome as a Significant Comorbidity in Sickle Cell Disease
    Afrin, Lawrence B.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2014, 348 (06) : 460 - 464
  • [4] Sensitization of nociceptive spinal neurons contributes to pain in a transgenic model of sickle cell disease
    Cataldo, Giuseppe
    Rajput, Sugandha
    Gupta, Kalpna
    Simone, Donald A.
    PAIN, 2015, 156 (04) : 722 - 730
  • [5] Safety and Utility of Quantitative Sensory Testing among Adults with Sickle Cell Disease: Indicators of Neuropathic Pain?
    Ezenwa, Miriam O.
    Molokie, Robert E.
    Wang, Zaijie Jim
    Yao, Yingwei
    Suarez, Marie L.
    Pullum, Cherese
    Schlaeger, Judith M.
    Fillingim, Roger B.
    Wilkie, Diana J.
    PAIN PRACTICE, 2016, 16 (03) : 282 - 293
  • [6] PKCδ-targeted intervention relieves chronic pain in a murine sickle cell disease model
    He, Ying
    Wilkie, Diana J.
    Nazari, Jonathan
    Wang, Rui
    Messing, Robert O.
    DeSimone, Joseph
    Molokie, Robert E.
    Wang, Zaijie Jim
    JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (08) : 3053 - 3057
  • [7] International Differences in Outpatient Pain Management: A Survey of Sickle Cell Disease
    El-Amin, Nadirah
    Nietert, Paul
    Kanter, Julie
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (12)
  • [8] Clinically significant differences in the visual analog pain scale in acute vasoocclusive sickle cell crisis
    Lopez, Bernard L.
    Flenders, Pamela
    Davis-Moon, Linda
    Corbin, Theodore
    Ballas, Samir K.
    HEMOGLOBIN, 2007, 31 (04) : 427 - 432
  • [9] Sickle cell disease: a natural model of acute and chronic pain
    Brandow, Amanda M.
    Zappia, Katherine J.
    Stucky, Cheryl L.
    PAIN, 2017, 158 (04) : S79 - S84
  • [10] Gut microbiota dysbiosis alters chronic pain behaviors in a humanized transgenic mouse model of sickle cell disease
    Kashyap, Yavnika
    Wang, Zaijie Jim
    PAIN, 2024, 165 (02) : 423 - 439